Erratum : Late-Onset Immune Checkpoint Inhibitor-Associated Nephrotoxicity and Suspected Thrombotic Microangiopathy Following Durvalumab Administration with a Challenging Clinical Course: A Case Report

Key Points

• To report a case of late-onset nephrotoxicity and suspected thrombotic microangiopathy following Durvalumab treatment.
• Detailed case report of clinical observations and interventions.
• Assessment of patient symptoms and treatments post-Durvalumab administration.
• Monitoring patient response to therapies and medical interventions.
• Identified nephrotoxicity linked to immune checkpoint inhibitor therapy.
• Documented suspected thrombotic microangiopathy in the patient.
• Observed challenging clinical course requiring complex management.